ASX:ACR Acrux (ACR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Acrux Stock (ASX:ACR) 30 days 90 days 365 days Advanced Chart Remove Ads Get Acrux alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume4,000 shsAverage VolumeN/AMarket Capitalization$12.47 millionP/E RatioN/ADividend Yield11.66%Price TargetN/AConsensus RatingN/A Company OverviewAcrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of males. It also provides estradiol transdermal sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause; and lidocaine and prilocaine cream, a generic version of EMLA cream, which is indicated as a topical anaesthetic for use on normal intact skin for local analgesia, and genital mucous membranes for superficial minor surgery and as a pre-treatment for infiltration anaesthesia. The company was incorporated in 1998 and is based in West Melbourne, Australia.Read More… Remove Ads Receive ACR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acrux and its competitors with MarketBeat's FREE daily newsletter. Email Address ACR Stock News HeadlinesAcrux Secures $1.73 Million Advance on R&D Tax IncentiveApril 2 at 8:42 PM | tipranks.comSouth African group buys Cononish gold mineMarch 13, 2025 | uk.finance.yahoo.comTrump’s Great Society Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 3, 2025 | Porter & Company (Ad)Acrux Limited Reports Significant Revenue Decline and Increased LossesFebruary 25, 2025 | tipranks.comAcrux Limited Announces Investor Webinar to Discuss Half-Year ResultsFebruary 25, 2025 | tipranks.comAcrux Limited Highlights Future Prospects in Topical PharmaceuticalsFebruary 25, 2025 | tipranks.comAcrux Limited Announces Issuance of New OptionsFebruary 18, 2025 | tipranks.comAcrux Limited Announces Changes in Director’s Securities HoldingsFebruary 18, 2025 | tipranks.comSee More Headlines ACR Stock Analysis - Frequently Asked Questions How were Acrux's earnings last quarter? Acrux Limited (ASX:ACR) released its earnings results on Thursday, February, 21st. The company reported ($0.02) EPS for the quarter. Acrux had a negative net margin of 113.93% and a negative trailing twelve-month return on equity of 130.13%. What other stocks do shareholders of Acrux own? Based on aggregate information from My MarketBeat watchlists, some other companies that Acrux investors own include Altimmune (ALT), ANZ Group (ANZ), Lynas Rare Earths (LYC), MV Oil Trust (MVO), Organigram (OGI), BHP Group (BHP) and Beacon Roofing Supply (BECN). Company Calendar Last Earnings2/21/2019Today4/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryTrading Current SymbolASX:ACR CIKN/A Webwww.acrux.com.au Phone+61-3-83790100FaxN/AEmployees2,018Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,800,000.00 Net Margins-113.93% Pretax MarginN/A Return on Equity-130.13% Return on Assets-48.18% Debt Debt-to-Equity Ratio113.06 Current Ratio1.61 Quick Ratio2.89 Sales & Book Value Annual Sales$5.09 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.57 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares290,720,000Free FloatN/AMarket Cap$12.47 million OptionableNot Optionable Beta1.21 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (ASX:ACR) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acrux Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Acrux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.